title: Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party.
abstract: In a retrospective study, data from 302 patients with metastatic testicular seminoma treated with chemotherapy between 1978 and 1990 in 10 European centres were analysed to evaluate the role, if any, of postchemotherapy treatment with irradiation. The primary endpoint of this study was the progression-free survival rate after chemotherapy with or without additional radiotherapy. This was related to the type of primary chemotherapy, sites and sizes of pre- and postchemotherapy masses, the extent of surgical resection after chemotherapy and the use of radiotherapy. 174 patients had residual disease at the end of chemotherapy. The most important prognostic factors for progression were the presence of any visceral metastases or raised LDH prechemotherapy, and the presence of residual disease at visceral sites after chemotherapy. Approximately half the patients with residual masses underwent postchemotherapy radiotherapy, with selection based predominantly on institutional practice. In patients receiving platinum-based chemotherapy, no significant difference was detected in progression-free survival whether or not radiotherapy was employed. Patients receiving BEP (bleomycin, etoposide and cisplatin) had a progression-free survival rate of 88% (95% CI, 80-96%) uninfluenced by postchemotherapy radiotherapy. In patients with residual masses confined to the abdomen after platinum-based chemotherapy, the absolute benefit to radiotherapy was estimated to be 2.3%. The potential benefit of postchemotherapy radiotherapy is minimal, and so it is concluded that the use of adjuvant radiotherapy to residual masses after platinum-based chemotherapy for metastatic seminoma is unnecessary.
authors.affiliation: Department of Oncology, UCL Medical School, Middlesex Hospital, London, U.K.
authors.forename: G M
authors.initials: GM
authors.lastname: Duchesne
authors.forename: S P
authors.initials: SP
authors.lastname: Stenning
authors.forename: N
authors.initials: N
authors.lastname: Aass
authors.forename: G M
authors.initials: GM
authors.lastname: Mead
authors.forename: S D
authors.initials: SD
authors.lastname: Fosså
authors.forename: R T
authors.initials: RT
authors.lastname: Oliver
authors.forename: A
authors.initials: A
authors.lastname: Horwich
authors.forename: G
authors.initials: G
authors.lastname: Read
authors.forename: I T
authors.initials: IT
authors.lastname: Roberts
authors.forename: G
authors.initials: G
authors.lastname: Rustin
authors.forename: M H
authors.initials: MH
authors.lastname: Cullen
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
authors.forename: S J
authors.initials: SJ
authors.lastname: Harland
authors.forename: P A
authors.initials: PA
authors.lastname: Cook
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D018239:Seminoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary*; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin